Kalbitor ecallantide: Phase II started

Cubist began the double-blind, placebo-controlled, U.S. Phase II CONSERV-1 trial to evaluate 3 dosages of IV ecallantide in about 300 patients undergoing on-pump cardiothoracic surgery. The company ha...